Summary: Preventive and curative paradigms of DED treatment can be modeled in vivo by exposure to a combination of the SiccaSystem environment and transdermic administration of scopolamine.
Dry-eye disease (or Keratoconjunctivitis sicca; DED) is defined by the International Dry Eye Workshop (DEWS) as a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.
Dry-eye disease is induced in mice by exposure to a controlled desiccating environment (SiccaSystemTM, K&P Scientific LLC, Oak Park, IL) and transdermal scopolamine administration (Novartis, Basel, Switzerland).
At Experimentica, we offer validated prophylactic and therapeutic paradigms of the experimental study design.
|Method of induction||Desiccating stress/ scopolamine|
|Follow-up period||Typically 2 – 3 weeks|
|Route of compound administration||Topical, systemic|
|Read-outs||1. Tear volume measurement;|
2. Corneal fluorescein staining;
3. Lacrimal gland pathology;
4. Quantification of conjunctival goblet cells;
5. Corneal morphology.
Outcomes and Read-Outs
Representative Example of Quantification of Corneal Surface Damage and Inflammation.
- Ziniauskaite A, Ragauskas A, Hakkarainen J, Rich C, Baumgartner R, Kalesnykas G, Albers D, and Kaja S. Efficacy of trabodenoson in a mouse keratoconjunctivitis sicca (KCS) model for dry-eye syndrome. Invest Ophthalmol Vis Sci. 2018.
- Kaja S, Ragauskas S, Ziniauskaite A, Haapaniemi AM, Hakkarainen JJ, Martiskainen H, Kalesnykas G. Use of approved drugs for dry-eye disease as reference compounds in the SiccaSystem(TM) standardized murine desiccating stress model. ARVO 2018 poster presentation.
- Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME, Pflugfelder SC. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002 Mar;43(3):632-8. PubMed PMID: 11867577.
- Arumugham R, Somasekhar G, Upadhyay AK, Kalesnykas G, Kaja S, Jain S. Pre-clinical efficacy of OCU300 nano emulsion for the treatment of ocular graft versus host disease. ARVO 2018, programme #3287.